Ann Dermatol.  2011 Dec;23(Suppl 3):S360-S363. 10.5021/ad.2011.23.S3.S360.

Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec(TM))

Affiliations
  • 1Department of Dermatology, College of Medicine, Chungnam National University, Daejeon, Korea. jhoon@cnu.ac.kr

Abstract

Imatinib mesylate (Gleevec(TM), STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use has been associated with various adverse cutaneous reactions, pityriasis rosea-like drug eruptions are rare. Here, we report a case of pityriasis rosea-like drug eruption that developed following the administration of imatinib mesylate to treat CML.

Keyword

Imatinib mesylate; Pityriasis rosea

MeSH Terms

Benzamides
Drug Eruptions
Gastrointestinal Stromal Tumors
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Mesylates
Piperazines
Pityriasis
Pityriasis Rosea
Pyrimidines
Imatinib Mesylate
Benzamides
Mesylates
Piperazines
Pyrimidines

Figure

  • Fig. 1 (A~D) Erythematous scaly patches are seen distributed along the cleavage lines of the trunk and extremities.

  • Fig. 2 (A, B) Acanthosis, parakeratosis, spongiosis, lymphocyte exocytosis, and the presence of necrotic keratinocytes in the epidermis. Vacuolar alterations at the dermo-epidermal junction are evident. Infiltration by lymphocytes and a smaller number of eosinophils, and extravasation of red blood cells are observed in the superficial dermis (H&E; ×40, ×100). (C, D) The intraepidermal lymphocytes are primarily CD8+ T cells; and the dermal perivascular and interstitial lymphocytes, primarily CD4+ T cells (C: CD4, D: CD8, ×100).


Reference

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001. 344:1031–1037.
Article
2. Valeyrie L, Bastuji-Garin S, Revuz J, Bachot N, Wechsler J, Berthaud P, et al. Adverse cutaneous reactions to imatinib (STI571) in Philadelphia chromosome-positive leukemias: a prospective study of 54 patients. J Am Acad Dermatol. 2003. 48:201–206.
Article
3. Hsiao LT, Chung HM, Lin JT, Chiou TJ, Liu JH, Fan FS, et al. Stevens-Johnson syndrome after treatment with STI571: a case report. Br J Haematol. 2002. 117:620–622.
Article
4. Brouard MC, Prins C, Mach-Pascual S, Saurat JH. Acute generalized exanthematous pustulosis associated with STI-571 in a patient with chronic myeloid leukemia. Dermatology. 2001. 203:57–59.
Article
5. Schwarz M, Kreuzer KA, Baskaynak G, Dörken B, le Coutre P. Imatinib-induced acute generalized exanthematous pustulosis (AGEP) in two patients with chronic myeloid leukemia. Eur J Haematol. 2002. 69:254–256.
Article
6. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001. 344:1038–1042.
Article
7. Yoo KH, Rho YK, Kim JY, Li K, Seo SJ, Hong CK. A case of drug eruption with localized exfoliative dermatitis induced by imatinib mesylate. Korean J Dermatol. 2008. 46:1435–1438.
8. Joo YH, Min SU, Lee DH, Suh DH. A case of drug eruption with periorbital edema and exfoliative dermatitis induced by imatinib mesylate (STI571, Gleevec(TM)). Korean J Dermatol. 2007. 45:194–196.
9. Bae YI, Yun SJ, Lee JB, Kim SJ, Lee SC, Won YH. A case of psoriasiform drug eruption induced by imatinib mesylate (Gleevec™). Korean J Dermatol. 2009. 47:722–725.
10. Woo SM, Huh CH, Park KC, Youn SW. Exacerbation of psoriasis in a chronic myelogenous leukemia patient treated with imatinib. J Dermatol. 2007. 34:724–726.
Article
11. Konstantopoulos K, Papadogianni A, Dimopoulou M, Kourelis C, Meletis J. Pityriasis rosea associated with imatinib (STI571, Gleevec). Dermatology. 2002. 205:172–173.
Article
12. Brazzelli V, Prestinari F, Roveda E, Barbagallo T, Bellani E, Vassallo C, et al. Pityriasis rosea-like eruption during treatment with imatinib mesylate: description of 3 cases. J Am Acad Dermatol. 2005. 53:5 Suppl 1. S240–S243.
Article
13. Lim DS, Muir J. Oral lichenoid reaction to imatinib (STI 571, Gleevec). Dermatology. 2002. 205:169–171.
Article
14. Basso FG, Boer CC, Corrêa ME, Torrezan M, Cintra ML, de Magalhães MH, et al. Skin and oral lesions associated to imatinib mesylate therapy. Support Care Cancer. 2009. 17:465–468.
Article
15. Rozieres A, Vocanson M, Saïd BB, Nosbaum A, Nicolas JF. Role of T cells in nonimmediate allergic drug reactions. Curr Opin Allergy Clin Immunol. 2009. 9:305–310.
Article
16. Brouard M, Saurat JH. Cutaneous reactions to STI571. N Engl J Med. 2001. 345:618–619.
Article
17. Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cardo C. Expression of c-kit and kit ligand proteins in normal human tissues. J Histochem Cytochem. 1994. 42:1417–1425.
Article
18. Scott LC, White JD, Reid R, Cowie F. Management of skin toxicity related to the use of imatinib mesylate (STI571, Glivectrade mark) for advanced stage gastrointestinal stromal tumours. Sarcoma. 2005. 9:157–160.
Article
19. Rule SA, O'Brien SG, Crossman LC. Managing cutaneous reactions to imatinib therapy. Blood. 2002. 100:3434–3435.
Article
Full Text Links
  • AD
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr